glp 1 and kidney disease GLP-1 receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal Glucagon-like peptide-1 receptor agonists in

FAO generates NADH, FADH2, and acetyl coenzyme A (CoA) in each round, 163 and NADH and FADH2 enter the ETC while the acetyl CoA enters the TCA cycle to produce citrate, which is exported to the cytosol to engage in NADPH production through ME1 and IDH1

GHK-Cu acts as a copper-binding signalling peptide that modulates the expression of thousands of genes involved in collagen remodelling, antioxidant defence, and tissue repair

A members-only digital community for a judgment-free space with peer groups for life on weight management medications

Metformin Evidence: Long-term studies (including the TAME trial) show improved cardiovascular health, reduced inflammation, and lower all-cause mortality in diabetics